Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years
Authors:
- Rosella TomaninRTRosella Tomanin
- Alessandra ZanettiAZAlessandra Zanetti
- Francesca D’avanzoFDFrancesca D’avanzo
- Angelica RampazzoARAngelica Rampazzo
- Nicoletta GasparottoNGNicoletta Gasparotto
- Rossella PariniRPRossella Parini
- Antonia PascarellaAPAntonia Pascarella
- Daniela ConcolinoDCDaniela Concolino
- Elena ProcopioEPElena Procopio
- Agata FiumaraAFAgata Fiumara
- Andrea BorgoABAndrea Borgo
- Anna Chiara FrigoAFAnna Chiara Frigo
Open Access
- 18 September 2014
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 129
Abstract
Hunter Syndrome is an X-linked lysosomal storage disorder due to the deficit of iduronate 2-sulfatase, an enzyme catalysing the degradation of the glycosaminoglycans (GAG) dermatan- and heparan-sulfate. Treatment of the disease is mainly performed by Enzyme Replacement Therapy (ERT) with idursulfase, in use since 2006. Clinical efficacy of ERT has been monitored mainly by the Hunter Outcome Survey (HOS) while very few independent studies have been so far conducted. The present study is a 3.5-years independent follow-up of 27 Hunter patients, starting ERT between 1.6 and 27 years of age, with the primary aim to evaluate efficacy of the therapy started at an early age (5 and ≤ 12 years and > 12 years. Patients were analysed both as 3 separate groups and also as one group; in addition, the 20 patients who started ERT up to 12 years of age were analysed as one group. Finally, patients presenting a 'severe' phenotype were compared with "attenuated" ones. Data analysis revealed a statistically significant reduction of the urinary GAG in patients ≤5 years and ≤ 12 years and of the hepatomegaly in the group aged >5 and ≤ 12 years. Although other clinical signs improved in some of the patients monitored, statistical analysis of their variation did not reveal any significant changes following enzyme administration. The evaluation of ERT efficacy in relation to the severity of the disease evidenced slightly higher improvements as for hepatomegaly, splenomegaly, otological disorders and adenotonsillar hypertrophy in severe vs attenuated patients. Although the present protocol of idursulfase administration may result efficacious in delaying the MPS II somatic disease progression at some extent, in this study we observed that several signs and symptoms did not improve during the therapy. Therefore, a strict monitoring of the efficacy obtained in the patients under ERT is becoming mandatory for clinical, ethical and economic reasons.Keywords
This publication has 38 references indexed in Scilit:
- Mucopolysaccharidosis: Cardiologic features and effects of enzyme‐replacement therapy in 24 children with MPS I, II and VIJournal of Inherited Metabolic Disease, 2012
- Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare diseaseOrphanet Journal of Rare Diseases, 2011
- The role of enzyme replacement therapy in severe Hunter syndrome—an expert panel consensusEuropean Journal of Pediatrics, 2011
- No evidence of association between complement factor I genetic variant rs10033900 and age-related macular degenerationEuropean Journal of Human Genetics, 2011
- Clinical utility gene card for: Mucopolysaccharidosis type IIEuropean Journal of Human Genetics, 2011
- Brain and spine MRI features of Hunter disease: frequency, natural evolution and response to therapyJournal of Inherited Metabolic Disease, 2011
- Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end pointsJournal of Inherited Metabolic Disease, 2011
- Pricing and reimbursement of orphan drugs: the need for more transparencyOrphanet Journal of Rare Diseases, 2011
- Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapyEuropean Journal of Pediatrics, 2007
- Smoothing reference centile curves: The lms method and penalized likelihoodStatistics in Medicine, 1992